Editas Medicine
EDIT----
Editas Medicine (EDIT)
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Editas Medicine Analyst Rating
View MoreForecast & Rating
May 27, 2026Price forecast
$5.78122.22%
Forecast & RatingBuy
13analysts
- Strong buy53.85%
- Buy0.00%
- Hold30.77%
- Sell0.00%
- Strong sell15.38%
News
- Market Beat · Jul 17 at 02:40 AM
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next?
- Global Report · Jul 4 at 04:01 AM
The Biotech Survival Curve: How Milestone Checks and In-Vivo CRISPR Are Rewriting the Rules
- Tip Ranks · Jun 18 at 04:50 PM
Editas Medicine Shareholders Back Board, Pay and Auditor
- PUBT · Jun 18 at 03:29 PM
Editas Medicine shareholders elect Connaughton, Levy as Class I directors at annual meeting
- Quartr · Jun 17 at 08:28 AM
EDIT: Director elections, compensation, and auditor ratification passed; EDIT-401 clinical plans advanced
- nasdaq · May 31 at 12:10 PM
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
